Director, Regulatory Affairs Labelling, Europe

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

As part of our expanding European organization, we seek a Director, Regulatory Affairs Labelling, Europe who will drive cross‑functional development and execution of regional labelling strategy with a primary focus on EU/EEA, UK, and Switzerland for designated programs.

This individual will lead EU labelling strategy and execution across development and post‑approval phases, ensuring compliance with EMA and national competent authority requirements, while maintaining alignment with global labelling.

They will independently represent European labelling on global and regional cross‑functional teams, delivering targeted, strategic and actionable labelling guidance for oncology programs across one or more therapeutic areas.

The candidate must have a thorough understanding of oncology drug development, applicable European regulations and is responsible for driving labelling interactions with health authorities including the EMA/MHRA/Swiss medic ensuring successful regulatory outcomes.

The role will report to the Senior Director, Regulatory Affairs, Europe.

• Lead the development and execution of EU labelling strategy in alignment with global regulatory strategy.

• Manage the preparation of high‑quality labelling documents, including EU/UK/Swiss Product Information.

• Contribute to target and core labelling documents from a regional perspective, as applicable.

• Oversight of EU PL user testing and translations of EU labelling documents.

• In partnership with Global RA Labelling, ensure consistency and alignment between core labelling and regional (EU) labelling.

• Serve as the EU labelling subject matter expert, advising internal stakeholders on EMA and regional labelling requirements, guidelines, and trends.

• Collaborate with Global RA Labelling, Clinical, Safety, Medical Affairs, Commercial, and other functions to develop and refine regional labelling content.

• Drive labelling strategy to support regulatory submissions (e.g., MAA, variations, renewals) and lifecycle management activities in Europe.

• Interface with EMA, rapporteurs, and national competent authorities on labelling‑related matters, including negotiations and responses to regulatory questions.

• Conduct competitive intelligence and benchmarking of EU labelling within the therapeutic area to inform strategy and positioning.

• Monitor evolving EU regulatory requirements and assess impact on labelling strategy and processes.

• Ensure high‑quality EU labelling deliverables through rigorous review, proofreading, and quality control processes.

• Oversee implementation and communication of approved EU labelling updates to relevant stakeholders.

• Maintain compliant documentation and version control for all EU labelling changes.

• Contribute to the development and continuous improvement of global labelling processes, tools, and policies.

• Oversee external vendors and CROs to ensure timely, high‑quality regulatory submissions and approvals.

• Degree in biological or life sciences, pharmacy, medicine, or related fields. An advanced degree (PhD, PharmD, MSc) is desirable.

• A minimum of 10 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a relevant labelling role.

• Significant experience with oncology drug development highly preferred.

• Demonstrated experience managing EU labelling (SmPC/PL) and…